The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Genomic DNA methylation: the mark and its mediators.
Klose, R. J., & Bird, A. P. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.12.008 · Cited by 2,501
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
The Draft Genome of Ciona intestinalis : Insights into Chordate and Vertebrate Origins
Dehal, P., Satou, Y., Campbell, R. K., Chapman, J., Degnan, B., De Tomaso, A., Davidson, B., Di Gregorio, A., Gelpke, M., Goodstein, D. M., et al. (2002) · Science · doi:10.1126/science.1080049 · Cited by 1,641
Joazeiro, C. A. P., & Weissman, A. M. (2000) · Cell · doi:10.1016/s0092-8674(00)00077-5 · Cited by 1,249
Glinsky, G. V., Berezovska, O., & Glinskii, A. B. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23412 · Cited by 916
MDM2–HDAC1-mediated deacetylation of p53 is required for its degradation
Ito, A., Kawaguchi, Y., Lai, C., Kovacs, J. J., Higashimoto, Y., Appella, E., & Yao, T. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf616 · Cited by 570
Cited by
Interpreting the language of histone and DNA modifications
Rothbart, S. B., & Strahl, B. D. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.001 · Cited by 720
Stefanska, B., Karlic, H., Varga, F., Fabianowska‐Majewska, K., & Haslberger, A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02002.x · Cited by 200
Digging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84
“Even for drugs thought to selectively target a certain oncogenic protein, such as Bcr-Abl or janus kinase 2 (Jak2), many ‘‘off-target’’ molecules are being found, as scientists dig deeper into their mechanisms of action.”
BackgroundA patent review of berberine and its derivatives with various pharmacological activities (2016–2020)
Kong, Y., Li, L., Zhao, L.-G., Yu, P., & Li, D.-D. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1974001 · Cited by 52
Metadata
- Authors
- Bronner, C., Achour, M., Arima, Y., Chataigneau, T., Saya, H., & Schini-Kerth, V. B.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 115
- Issue
- 3
- Pages
- 419-434
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2057964641
- Cited by
- 159
- References
- 13
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future? https://app.cochat.ai/papers/10.1016/j.pharmthera.2007.06.003
- The paper
- Bronner, C., Achour, M., Arima, Y., Chataigneau, T., Saya, H., & Schini-Kerth, V. B. (2007). The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future? Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2007.06.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.